Ribociclib HYDROCHLORIDE

Description: Ribociclib HCl (formerly also known as LEE011, NVP-LEE011; trade name: Kisqali) is an orally bioavailable, potent and highly specific inhibitor of CDK4/6 (cyclin-dependent kinase) with IC50s of 10 nM and 39 nM, respectively. As of March 2017, Ribociclib was approved by FDA to treat postmenopausal women with a type of advanced breast cancer. Ribociclib functions via decreasing in phosphorylated RB and FOXM1. When tested with 17 human neuroblastoma cell lines, 12 of them were sensitive to Ribociclib treatment with mean IC50=306+/-68 NM. Treatment with Ribociclib could dramatically decrease cell growth via arresting cell cycle G0-G1. In 12 of 17 human neuroblastoma-derived cell lines, treatment with LEE011 could significantly reduce cell proliferation.

References: Clin Cancer Res. 2013 Nov 15; 19(22):6173-82.

Related CAS#:1374639-79-8 (succinate hydrate); 1211441-98-3 (free base); 1374639-75-4 (succinate); 1211441-98-3 (free base)